File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate.

TitleAndrogen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate.
Authors
Issue Date2014
PublisherHindawi. The Journal's web site is located at http://www.hindawi.com/journals/jo/
Citation
Journal of Oncology, 2014, v. 2014, article no. 529468 How to Cite?
AbstractBackground. Androgen deprivation therapy (ADT) in nonmetastatic prostate cancer is unclear. Recent data suggests possible increase in the cardiovascular risks receiving ADT. The aim of the study was to investigate the cardiovascular outcomes in a cohort of Chinese nonmetastatic prostate cancer patients with no previously documented cardiovascular disease. Methods and Results. 745 patients with no previously documented cardiovascular disease and/or diabetes mellitus diagnosed to have nonmetastatic prostate cancer were recruited. Of these, 517 patients received ADT and the remaining 228 did not. After a mean follow-up of 5.3 years, 60 patients developed primary composite endpoint including (1) coronary artery disease, (2) congestive heart failure, and (3) ischemic stroke. Higher proportion of patients on ADT (51 patients, 9.9%) developed composite endpoint compared with those not on ADT (9 patients, 3.9%) with hazard ratio (HR) of 2.06 (95% confidence interval (CI): 1.03–3.24, ). Furthermore, Cox regression analysis revealed that only the use of ADT (HR: 2.1, 95% CI: 1.03–4.25, ) and hypertension (HR: 2.0, 95% CI: 1.21–3.33, ) were independent predictors for primary composite endpoint. Conclusion. ADT in Chinese patients with nonmetastatic prostate cancer with no previously documented cardiovascular disease was associated with subsequent development of cardiovascular events.
Persistent Identifierhttp://hdl.handle.net/10722/205929
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorHuang, Gen_US
dc.contributor.authorYeung, CYen_US
dc.contributor.authorLee, KKen_US
dc.contributor.authorLIU, Jen_US
dc.contributor.authorHo, KLen_US
dc.contributor.authorYIU, MKen_US
dc.contributor.authorLam, KSLen_US
dc.contributor.authorTse, HFen_US
dc.contributor.authorYau, TCCen_US
dc.contributor.authorSiu, DCWen_US
dc.date.accessioned2014-10-20T09:55:35Z-
dc.date.available2014-10-20T09:55:35Z-
dc.date.issued2014en_US
dc.identifier.citationJournal of Oncology, 2014, v. 2014, article no. 529468en_US
dc.identifier.urihttp://hdl.handle.net/10722/205929-
dc.description.abstractBackground. Androgen deprivation therapy (ADT) in nonmetastatic prostate cancer is unclear. Recent data suggests possible increase in the cardiovascular risks receiving ADT. The aim of the study was to investigate the cardiovascular outcomes in a cohort of Chinese nonmetastatic prostate cancer patients with no previously documented cardiovascular disease. Methods and Results. 745 patients with no previously documented cardiovascular disease and/or diabetes mellitus diagnosed to have nonmetastatic prostate cancer were recruited. Of these, 517 patients received ADT and the remaining 228 did not. After a mean follow-up of 5.3 years, 60 patients developed primary composite endpoint including (1) coronary artery disease, (2) congestive heart failure, and (3) ischemic stroke. Higher proportion of patients on ADT (51 patients, 9.9%) developed composite endpoint compared with those not on ADT (9 patients, 3.9%) with hazard ratio (HR) of 2.06 (95% confidence interval (CI): 1.03–3.24, ). Furthermore, Cox regression analysis revealed that only the use of ADT (HR: 2.1, 95% CI: 1.03–4.25, ) and hypertension (HR: 2.0, 95% CI: 1.21–3.33, ) were independent predictors for primary composite endpoint. Conclusion. ADT in Chinese patients with nonmetastatic prostate cancer with no previously documented cardiovascular disease was associated with subsequent development of cardiovascular events.en_US
dc.languageengen_US
dc.publisherHindawi. The Journal's web site is located at http://www.hindawi.com/journals/jo/en_US
dc.relation.ispartofJournal of Oncologyen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleAndrogen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate.en_US
dc.typeArticleen_US
dc.identifier.emailLam, KSL: ksllam@hku.hken_US
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailSiu, DCW: cwdsiu@hkucc.hku.hken_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authoritySiu, DCW=rp00534en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1155/2014/529468-
dc.identifier.pmid24803931-
dc.identifier.pmcidPMC3997904-
dc.identifier.hkuros241219en_US
dc.identifier.hkuros232553-
dc.identifier.volume2014en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats